Invus US Partners LLC - 01 Aug 2022 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role
Director, 10%+ Owner
Signature
Invus US Partners LLC, By: /s/ Philip Bafundo , Name: Philip Bafundo, Title: Authorized Person
Issuer symbol
LXRX
Transactions as of
01 Aug 2022
Net transactions value
+$2,456,500
Form type
4
Filing time
01 Aug 2022, 16:15:28 UTC
Next filing
09 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LXRX Common Stock Purchase $2,456,500 +982,600 +23% $2.50 5,303,814 01 Aug 2022 See Footnotes F1, F2, F4, F5
holding LXRX Common Stock 331,545 01 Aug 2022 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 27, 2022, Invus US Partners LLC entered into a purchase agreement with the Issuer pursuant to which Invus US Partners LLC agreed to purchase 982,600 shares of common stock, $0.001 par value per share (the "Issuer Common Stock") of the Issuer at a price of $2.50 per share. The purchase closed on August 1, 2022.
F2 These securities are directly held by Invus US Partners LLC
F3 These securities are directly held by Mr. Raymond Debbane.
F4 Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.
F5 Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.

Remarks:

Artal International S.C.A. directly holds 48,433,261 shares of Issuer Common Stock; Invus, L.P. directly holds 35,402,689 shares of Issuer Common Stock; and Invus Public Equities, L.P. directly holds 3,516,214 shares of Issuer Common Stock, which securities are being reported on a separately filed Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.